期刊
DIABETES CARE
卷 40, 期 10, 页码 1364-1372出版社
AMER DIABETES ASSOC
DOI: 10.2337/dc17-0518
关键词
-
资金
- Astellas
- AstraZeneca
- Ono
- Merck Sharp Dohme (MSD)
- Boehringer Ingelheim
- Eli Lilly
- Kowa
- Mitsubishi Tanabe
- MSD
- Novartis
- Novo Nordisk
- Sanofi
- Taisho Toyama
- Takeda
- Chugai
- Daiichi Sankyo
- Kissei
- Kyowa Hakko Kirin
- Mochida
- Sanwa Kagaku Kenkyusho
- AbbVie
- Johnson Johnson
- Meiji Seika
- Shionogi
- Sumitomo Dainippon
OBJECTIVE To compare the efficacy of ipragliflozin versus pioglitazone in patients with type 2 diabetes complicated by nonalcoholic fatty liver disease (NAFLD). RESEARCH DESIGN AND METHODS In this open-label, randomized, active-controlled trial, we randomly assigned 66 patients with type 2 diabetes and NAFLD to receive ipragliflozin 50 mg (n = 32) or pioglitazone 15-30 mg (n = 34) orally once daily. The primary outcome was a change from-baseline in the liver-to-spleen attenuation ratio (L/S ratio) on computed tomography at week 24. RESULTS At week 24, the mean 6 SD L/S ratio had increased by 0.22 (from 0.80 +/- 0.24 to 1.00 +/- 0.18) in the ipragliflozin group and 0.21 (from 0.78 +/- 0.26 to 0.98 +/- 0.16) in the pioglitazone group (P = 0.90). Serum aspartate and alanine aminotransferase levels, HbA(1c), and fasting plasma glucose were similarly reduced in the two treatment groups. Nevertheless, body weight and visceral fat area showed significant reductions only in the ipragliflozin group compared with the pioglitazone group (P < 0.0001 and P = 0.0013, respectively). There were no serious adverse events in either group. CONCLUSIONS Compared with pioglitazone, ipragliflozin exerts equally beneficial effects on NAFLD and glycmic control during the treatment of patients with type 2 diabetes complicated by NAFLD. Furthermore, ipragliflozin significantly reduced body weight and abdominal fat area.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据